Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupFRA:C1P 78 Gross Margin % is 78.89% as of Dec. 2025, which is 5% above its 10-year median of 74.89. GuruFocus rates FRA:C1P with a GF Score™ of 78/100 and a GF Value™ of €0.92 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 941 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 90.22% on this metric.
Consun Pharmaceutical Group (FRA:C1P) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Consun Pharmaceutical Group had a gross margin of 78.89% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Consun Pharmaceutical Group Gross Margin % Related Terms
Consun Pharmaceutical Group Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Consun Pharmaceutical Group (FRA:C1P) has a Gross Margin % of 78.89% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Consun Pharmaceutical Group and its competitors. This is near median its historical median of 74.89. Over the past decade, Consun Pharmaceutical Group's Gross Margin % has ranged from 72.99 to 78.05. According to the industry distribution chart, Consun Pharmaceutical Group ranks #92 out of 941 companies in the Drug Manufacturers industry, placing it in the top 9.8%.
Is Consun Pharmaceutical Group's Gross Margin % too high?
Consun Pharmaceutical Group's current Gross Margin % of 78.89% is near median its 10-year median of 74.89. Over the past 10 years, this metric has ranged from a low of 72.99 to a high of 78.05. The Drug Manufacturers industry median Gross Margin % is 48.54. Consun Pharmaceutical Group's value of 78.89% is 62.5% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #92 out of 941 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #92 out of 941 companies for Gross Margin %. This places Consun Pharmaceutical Group in the top 10% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Consun Pharmaceutical Group's value of 78.89% is 62.5% above this benchmark. Historically, Consun Pharmaceutical Group's own Gross Margin % has ranged from 72.99 to 78.05 over the past decade. While the company's 10-year median is 74.89 vs. the industry median of 48.54, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Gross Margin % of 78.89% is 62.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Gross Margin % is 78.89%, which is near median its own 10-year median of 74.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (FRA:C1P) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.92, compared to a current price of €1.50 — trading 63% above its estimated fair value. The current Gross Margin % is 78.89%, which is near median its 10-year median of 74.89 and 62.5% above the Drug Manufacturers industry median of 48.54. Consun Pharmaceutical Group's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Consun Pharmaceutical Group (FRA:C1P), the current Gross Margin % is 78.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (FRA:C1P) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.50 is trading 63% above its estimated GF Value™ of €0.92.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for FRA:C1P:
Gross Margin %: 78.89% (near median its 10-year median of 74.89)
GF Value™: €0.92 vs. price of €1.50 (63% above fair value)
Industry Position: 62.5% above the Drug Manufacturers median (#92 of 941)
No single metric tells the full story. See the FRA:C1P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
78GF Score
Get the complete analysis for FRA:C1P
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C1P has been successfully added to your 
